Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
POS Field - Week 1 Spring
TNL_______2.19___________rojosi1
DXO_______2.75___________clearcoated
CNOA_______.29 pending___The_Fast_One
SSCC_______.602__________Adelheida
BCS_______3.07___________Mirre
GERN at close 7.09
DXO at 2.78 close
TURF Picks - Week 1 Spring 2009
Please "Public Reply" to this message when posting pony!
GL all
POS Picks - Week 1 Spring 2009
Please "Public Reply" to this message when posting pony!
GL all
The chart tells the story. There's never been a sustained uptrend.
I would like to think that it will happen eventually. Probably best advice is to wait until that uptrend starts.
The corporate update in Dec. was very encouraging, but now lets follow up with results and more PRs. If they can do that then there's some hope.
I remember that (what is now) $2.50 was considered VERY cheap. LOL....
Maybe I'm a fool but the corporate update PR 12-26-08 gives me some hope.
Averaging down is almost always a fools game, but when you can triple or quadruple down maybe it's worth the gamble. Because if it runs you're so much closer.
This stock has really been devalued. Even at 9.5 million shares this company is worth $84,000.
We'll see in Feb with CHBO's 10Q
Hi Fred, nice new home!
Opened Sept 15 at .05
http://chinabiopharma.net/Index_2_Read.asp?PressType=1&ID=86
China Biopharma, Inc. Issues Corporate Information Update
Hangzhou, China, December 26, 2008 - China Biopharma, Inc. (OTCBB: CHBO) issued corporate information updates today.
The Company had significant operational improvement after the start of corporate operational restructuring last year. For the nine months ended September 30, 2008, it has made approximately $5.4 million in sales, more than thirteen times the sales revenue made in the same period of 2007, which was approximately $0.4 million. It also made approximately $90,000 in net profit from the China operation, comparing to a net loss of approximately $0.35 million in the same period of 2007. The Company believes that the current operation will further improve as it finalizes the operational restructuring.
The Company has signed an agreement with Zhejiang Tianyuan Biopharma Co., Ltd. that the Company will increase its stakes from currently 65% to 100% in the joint venture, Zhejiang Tianyuan Biotech Co., Ltd. (“ZTBC”). ZTBC will become a wholly owned subsidiary of the Company, and will change its name to Zhejiang Kangchen Biotech Co., Ltd. It is waiting for the new business license.
The Company has signed an agreement to acquire 90% of Beijing Tiancheng Xinhai Pharmaceutical Co., Ltd. (“BTXP”), a regional pharmaceutical distribution company. The company now has full operating control in BTXP and is waiting for final governmental approval and new business license.
After completion of recent operational restructuring, the company is looking for future merge and acquisitions. The Company is projecting a 25% sales increase in 2009.
About China Biopharma, Inc.
China Biopharma, Inc. is a pharmaceutical company based in China. Through its operating subsidiaries, the company introduces and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include biopharmaceutical and other pharmaceutical drugs. Leveraging its local presence and the relationship with local Chinese pharmaceutical companies and international pharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as in new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.
http://chinabiopharma.net/Index_2_Read.asp?PressType=1&ID=87
yeah but Wang still has a huge financial stake in CHBO. Look at all the shares he, his family foundation or whatever own. He personally holds majority ownership and never sold a single share.
Saw this today FWIW: Peter Wang, Sinoquest, PR mentions Wang's China Biopharma CHBO
MOUNTAINSIDE, NJ -- (Marketwire) -- 12/15/08 -- Proteonomix, Inc. (PINKSHEETS: PROT) announces that its wholly-owned subsidiary, Proteoderm, Inc., and Sinoquest Investment Limited have signed a letter of intent (LOI), whereby, under a definitive agreement to be consummated, Sinoquest will gain exclusive rights in China, Taiwan, and Hong Kong to purchase for distribution of Proteoderm's revolutionary new stem cell-derived skin care products containing the bioactive protein matrix NC-138(TM). The products include Proteoderm's special high end formulation and an over-the-counter formulation, currently under development. Proteoderm intends to sell to Sinoquest the pre-mixed material in bulk and a license of its name and the right to use the material in Sinoquest's own containers. Both companies expect to begin distribution in the first quarter of 2009.
Peter Wang, President of Sinoquest, is a proven marketing expert in China. He founded and developed UTStarcom, Inc., which sold over 150 million personal handy phones in China, creating a multi-billion dollar business in eight years. Peter Wang is also Chief Executive Officer and Chairman of the Board of Directors of China Biopharma, Inc.
Michael Cohen, President of Proteonomix, commented, "After years of research and development, Proteoderm's products are now ready for commercialization. Proteoderm is pleased to enter this LOI with Sinoquest because of Sinoquest's ownership interests in several distribution networks including channels for pharmaceutical and cosmetic products in China. We are privileged to have Mr. Wang direct our sales and distribution in China, as well as Taiwan and Hong Kong. He has a proven track record of bringing new products to China and establishing them. Proteoderm is looking forward to a successful launch of its cosmoceutical products in China with Mr. Wang and Sinoquest."
Peter Wang, President of Sinoquest, stated, "We are very glad to sign an LOI with Proteoderm for distributing Proteoderm's unique skin care products. As the world's fastest growing economy, the Greater China region has demonstrated a huge market potential for high-end skin care products such as Proteoderm's cosmoceutical containing NC-138. We are very confident that these anti-aging products will become the leading stem cell-derived skin care products in the region."
About Proteonomix, Inc.
Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. It is developing an intellectual property portfolio in the areas of therapeutics and cosmetics. For more information, please visit www.proteonomix.com or www.proteoderm.com and www.pinksheets.com.
"Safe Harbor Statement"
Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto may not occur.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Michael Cohen
President
Proteonomix, Inc.
Phone: (973) 544-6116
Email Contact
Published Dec. 15, 2008
Copyright © 2008 SYS-CON Media. All Rights Reserved.
http://au.sys-con.com/node/778236
MSN is closing their message boards and asking groups to migrate to Multiply.
I belong to a small stock picking group that runs a weekly contest. Can we set up our group at iHub for free, or does it require a premium subscription?
Looking at the FAQ, I'm not sure if we are allowed to even set up a stock picking contest group for free.
I understand that if we want it private, then that's premium. Under the free category it would be public.
Soonfast receives China patents for anti-HPV/HSV herbal
Tuesday, September 2, 2008
On August 30th Soonfast Pharmaceutical Science & Technology Co. Ltd. announced its patents of herbal anti-HPV medicine had been approved by the State Intellectual Property Office of China.
The product had shown an inhibitory effect on the growth of human papilloma virus (HPV) and herpes simplex virus (HSV). Experiments have also proved that the herbal medicine is effective against multiple HPV types including 6, 11, 16, 18 and 33.
http://www.gbipharma.com/cpbheadlinefree.asp?newsid=2009057
CBPC
10Q for Q2 08 should be out soon...should see it this week
Hopefully with 7 mil shares CBPC will have some news and really pump that small float.
The R/S was approved by unanimous written consent of majority shareholders on July 3rd. So there was no need for a public vote on it. There's no doubt that it will happen.
The reason for R/S is because they maxed out their authorized shares at 700 mil. The R/S will make the outstanding shares to go to 7 mil, while keeping the authorized level at 700 mil... so it gives them additional room again in authorized shares.
http://www.sec.gov/Archives/edgar/data/1190132/000114420408041210/v120552_def14c.htm
By unanimous written consent dated July 3, 2008 the Board of Directors adopted an amendment to the Company’s Certificate of Incorporation (the “Amendment”) to effect a 1 for 100 reverse stock spit of the Company’s outstanding Common Stock and recommended that the Amendment and the reverse stock split contemplated thereby be approved by our stockholders. A copy of the unanimous written consent is attached hereto as Exhibit A. By written consent dated July 3, 2008, the holders of a majority of the outstanding shares of Common Stock approved the filing of the Amendment and the reverse split contemplated thereby. A copy of the stockholder consent is attached hereto as Exhibit B. A form of the Amendment is attached hereto as Exhibit C.
The Amendment will become effective when filed with the Secretary of State of the State of Delaware. The Company anticipates that the filing of the Amendment will occur on or about August 15, 2008. If the Amendment were not adopted by written consent of the stockholders, it would have to be considered by the stockholders at a special stockholders' meeting convened for the specific purpose of approving the Amendment.
CBPC R/S scheduled for August 15 per today's filing
http://www.sec.gov/Archives/edgar/data/1190132/000114420408041210/v120552_def14c.htm
The Amendment will become effective when filed with the Secretary of State of the State of Delaware. The Company anticipates that the filing of the Amendment will occur on or about August 15, 2008. If the Amendment were not adopted by written consent of the stockholders, it would have to be considered by the stockholders at a special stockholders' meeting convened for the specific purpose of approving the Amendment.
"Total loss if all Warrants exercised and sold at market on July 10, 2008 .... $4,904,160"
http://www.sec.gov/Archives/edgar/data/1190132/000114420408040840/v120371_prer14c.htm
That's 99.68% loss of a $4,920,000 value... unless I'm not understanding the deal.
Also, saw that the a/s stays at 700 mil following the r/s, while the o/s is projected to be 5 mil. But that is their reason for the r/s... to give them breathing room in the a/s.
I was wondering about something concerning all the warrants for China Biopharma.
How will the .40 warrants be effected by the R/S? Do they become $40.00 warrants after the 1:100 R/S or will they remain .40?
If they remain the same, the 1:100 R/S just brought them a lot closer to being able to exercise them.
PRER14C filed 1 for 100 reverse stock split CBPC
http://www.sec.gov/Archives/edgar/data/1190132/000114420408040076/v119882_prer14c.htm
DEFR14A filed: amended July 23 to August 15
Annual Meeting of Stockholders to be held on August 15, 2008, at 2:00 p.m. (EST), at Holiday Inn, 100 Independence Way, Princeton, New Jersey
The Company expects that the Notice of Annual Meeting, Proxy Statement and form of proxy will first be mailed to stockholders on or about July 22, 2008.
http://www.sec.gov/Archives/edgar/data/1190132/000114420408039673/v119758_defr14a.htm
holy crap. A write-off I couldn't afford. Anchored to the ship now whatever may happen. A lot of money.
I just said that... I'm just checking to see if I can get a response from this email address. There has been some concern that the email address isn't getting responses anymore.
They replied: The email works well. How can we help you?
I emailed this morning and got a response back in 3 hrs.
ir@chinabiopharma.net is the address
Just watching quietly here
Feel free to add DD suggestions and I'll do my best to update or edit per your requests. Or feel free to join as an assistant mod. Your input is appreciated.
Anyone with a suggestion can either post it or email me.
website is working fine
I just noticed business address has changed on SEC filings and on website.
It used to be entirely listed as Princeton NJ... now its entirely Hangzhou, China.
Business Address
75 SHUGUANG ROAD,
BUILDING B
HANGZHOU F4 310007
732-632-9896
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001190132&owner=include&count=40
http://chinabiopharma.net/index_6_1.asp
Greg Scott has his own "China Bio" agenda, he's biased and a partner in a hedgefund that focuses on biopharma investing in China. He pushes his own interests in his articles.
Vision Opportunity China Fund Limited ("VOC") announces the
completion of its first investment since listing on the AIM market.
http://www.digitallook.com/news/rns/1817141-856748/VOC-Initial_Investment.html
Vision Opportunity China Fund Ltd
20 December 2007
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN THE UNITED STATES, CANADA,
AUSTRALIA, REPUBLIC OF SOUTH AFRICA OR JAPAN
20 December 2007
Vision Opportunity China Fund Limited
Initial Investment
Vision Opportunity China Fund Limited ("VOC") announces the
completion of its first investment since listing on the AIM market. The Company
has made a $2.56 million investment in Astrata Group, Inc. (OTCBB:ATTG).
Astrata, based in Singapore, designs, develops, manufactures and sells
location-based IT services and solutions for homeland security and commercial
applications, worldwide.
In return for its investment, VOC received the following:
•preferred shares that are convertible into common shares of Astrata at
$0.70 per share;
•warrants to purchase approximately 1.83 million common shares of Astrata
at a purchase price of $1.00 per share and an additional 1.83 million common
shares at $1.50 per share; and
•the right to purchase an additional $2.56 million of preferred shares
over the next 12 months with warrants to purchase approximately 1.83 million
common shares of Astrata at a purchase price of $1.25 per share and warrants
to purchase 1.83 million common shares of Astrata at a purchase price of
$1.75 per share receivable upon making the additional investment.
VOC acted as the lead investor in the $3 million total financing, co-investing
alongside Vision Opportunity Master Fund Ltd, which is chartered and managed
independently from VOC. Astrata is an advanced location-based IT services and
solutions (telematics) business that enables businesses and institutions to
monitor, trace and control the movement and status of machinery, vehicles,
personnel or other assets. It has offices in Asia, the US and Europe.
The co-investment is in accordance with VOC's allocation guidelines and has been
approved by VOC's Investment Committee.
"We have watched Astrata successfully grow its business from a single contract
with the Singapore government to a substantial operation with contracts worth
more than $120 million with several sovereign governments and commercial
institutions. The business has also secured a major supply agreement with
Siemens AG (XETRA:SIE.DE)" stated Adam Benowitz, the portfolio manager of VOC at
Vision Capital Advisors, LLC.
Enquiries to:
Vision Opportunity China Fund Limited
David Benway, Director / Adam Benowitz, Portfolio Manager
www.vocfund.com Tel: +1 (212) 849 8225
Fairfax I.S. PLC
Paul Richards/ James King Tel: +44 (0) 20 7598 5368
Bankside Consultants Limited
Simon Rothschild/Oliver Winters Tel: +44 (0) 20 7367 8888
NOTE TO EDITORS
Vision Opportunity China Fund Limited
Vision Opportunity China Fund Limited ("VOC") is a closed end listed fund traded
on the AIM market of the London Stock Exchange plc (AIM) with current assets
under management of approximately $95 million. VOC primarily invests directly in
listed companies with operations principally within Greater China.
Greater China is a collective term for the territories administered by the
People's Republic of China, those administered by the Republic of China and
Singapore.
------------------------------------------------------------------------------------------------------------------
CBPC: http://investorshub.advfn.com/boards/read_msg.asp?message_id=24878609
"the Group will only make an investment in a company in which Vision Opportunity Master Fund
has an existing investment"
Some interesting "Vision Opportunity China Fund" links:
Investors with Vision Opportunity China Fund Ld Ord NPV in their portfolio also have the following
http://www.iii.co.uk/investment/detail?code=cotn:VOC.L&display=community&it=le
little message board
http://www.iii.co.uk/investment/detail?code=cotn:VOC.L&it=le
CBPC
DASEN® is one Takeda drug CBPC is distributing:
http://www.chinabiopharma.net/Index_2_Read.asp?PressType=&ID=67
Vision Opportunity China Fund
http://www.vocfund.com/pdf/Admission_Document.pdf
"the Group will only make an investment in a company in which Vision Opportunity Master Fund
has an existing investment"
CBPC
Rozerem... one of Takeda's brand name products
I was wondering who Takeda was... you've seen their sleeping aid commercials with Abe Lincoln, beaver, astronaut dream characters follwing that guy around
http://www.rozerem.com/consumer/voucher.aspx
CBPC distribution partner